In humans low intake or low levels of folate are related to elevated homocysteine (Hcy) or blood pressure (BP). This study was performed to test whether in healthy postmenopausal women a 3-week administration of folate (5-methyltetrahydrofolate: 5-MTHF) at the dose of 15 mg/day (n ¼ 15), was, in comparison to placebo (n ¼ 15), capable of modifying 24-h ambulatory BP, along with Hcy and insulin metabolism. Placebo did not modify any parameter. 5-MTHF significantly decreased nocturnal systolic (À4.48 ± 1.8 mm Hg; P ¼ 0.029), diastolic (À5.33 ± 1.3 mm Hg; P ¼ 0.001) and mean (À5.10 ± 1.1 mm Hg; P ¼ 0.005) BP, in a way that was significantly different from that observed during placebo. 5-MTHF also reduced Hcy (11.77 ± 1.15 vs 8.71 ± 0.50 mmol/l; P ¼ 0.03), and insulin resistance, evaluated by HOMA-IR (2.58 ± 0.04 vs 2.03 ± 0.04; P ¼ 0.01). Whether maintained in the long term, 5-MTHF's cardiovascular and metabolic effect may contribute to primary cardiovascular prevention of postmenopausal women.
Blood pressure (BP) increases with age, and in women, is further increased by postmenopausal hypoestrogenism (Staessen et al., 1989) . Elevated BP and homocysteine (Hcy) are found related to each other (Bates et al., 1997; Kahleová et al., 2002) , and both, are inversely related or decreased by folates (van DiJk et al., 2001; Kahleová et al., 2002; Mangoni et al., 2002; Forman et al., 2005; Anderson et al., 2006) . Data on folate supplementation and ambulatory BP are not available, particularly in individuals with no major cardiovascular risk factor. This double-blind study, approved by the local ethics committee and Institutional Review Board, was performed to evaluate modifications of ambulatory BP induced by a 3-week supplementation with 15 mg of active folate (5-methyltetrahydrofolate; 5-MTHF; Prefolic; Zambon SpA, Milan, Italy), in 15 healthy nonobese Caucasian women, 48-58 years of age, in natural menopause since, at least, 2 years. Other 15 women served as control, and received a placebo pill containing the same components of active pill but without folate. Assignment to treatment was performed following a balanced computer-generated list of randomization. Exclusion criteria were severe climacteric symptoms, hypertension requiring treatment, diabetes, thyroid disorders and, in the last 3 months, intake of hormones, multivitamins, folates or vitamin B12. Women were not consuming fortified foods or vitamins and were requested not to change their diet or lifestyle during the study.
Before and in the last 2 days of treatment, starting at 1700 hours, BP was sampled consecutively every 30 min for 41 h by an oscillometric BP monitoring device (ABP Monitor; Spacelabs Medical, Redmond, WA, USA). To minimize the effect of accommodation to the procedure, patients slept in their home and data of the first night were excluded. During recording, patients were requested to limit physical activity, avoid stressful events and consume no more than 2000 kcal/ die in 3 meals at fixed time. Body weight and fasting Hcy, insulin, glucose, cholesterol, high-density lipoproteins (HDL) and triglycerides were evaluated before and at the end of treatment. Levels of Hcy were assayed by high-performance liquid chromatography (HPLC) with fluorometric detection, using a commercially available HPLC kit (Bio-Rad, Munich, Germany); levels of insulin were measured by available radioimmunoassay kits (Biodata; Guidonia Montecelio, Rome, Italy), and the other biochemical parameters by common laboratory methods. Fasting glucose (mmol/l) and insulin (IU/l) were used to calculate the index of insulin resistance HOMA-IR (glucose Â insulin/22.5).
BP data, smoothed by a three-point moving average, were used at hourly intervals and analyzed by cosinor analysis. Rhythms were put in phase by considering the cosinor nadir of the mean blood pressure rhythm as the circadian time 0. Nighttime values were considered those including the 3 h preceding and following the nadir. Twentyfour hours, daytime and nighttime values were separately evaluated.
Mean (±s.e.) women characteristics and 24-h BP values along with their net modifications are reported in Tables 1  and 2 , respectively. All data were normally distributed. There was no difference between women receiving placebo or 5-MTHF, at baseline. Either 5-MTHF or placebo did not modify body weight and any biochemical parameter except for Hcy, insulin and HOMA-IR that were significantly reduced by 5-MTHF (Table 1) .
Administration of 5-MTHF significantly decreased nocturnal systolic, diastolic and mean BP, without modifying diurnal BP (Table 2 ). These modifications were significantly different from those observed during placebo (Table 2) . Following 5-MTHF the day-night BP difference (Table 2 ) and the numbers of dippers (nocturnal decline of mean BP 410%), who are at reduced cardiovascular risk (Verdecchia, 2000) , increased from 3 (20%) to 10 (66.6%; Po0.01; by w 2 -test). The decline of nocturnal mean BP induced by 5-MTHF was more pronounced in non-dippers (n ¼ 12) than in dippers (n ¼ 3; À6.1±1.1 vs 0.35±0.88 mm Hg; P ¼ 0.012, by Student's t-test), but it was not related to baseline BP, age, weight, body mass index and biochemical parameters including Hcy and its modification. Placebo did not modify diurnal or nocturnal BP. Dippers were 4 (26.6%) at baseline and 5 (33.3%) after treatment.
The herein reported capability of folate of decreasing BP agrees with previous data showing that a low intake (Forman et al., 2005) or low level (Kahleová et al., 2002) of folates is associated with hypertension, and that, in individuals at increased cardiovascular risk, folate supplementation reduces daytime office BP of about 4-5 mm Hg (van Dijk et al., 2001; Mangoni et al., 2002; Anderson et al., 2006) . In our data, daytime BP did not or only slightly decreased. Number of subjects would have been insufficient to document a significant effect, but also subject selection and method of BP measurement may be implicated in the different response obtained in this study. Undoubtedly, the effect of 5-MTHF on nighttime BP was stronger. Folate may favor a better sleep, or may amplify the effect of central or peripheral mechanisms involved in the nocturnal BP decline, although these hypotheses are momentarily unproven. Besides nocturnal BP, 5-MTHF decreased Hcy, insulin and insulin resistance, roughly determined by HOMA-IR. Improvement in insulin sensitivity by folate was previously reported (Villa et al., 2005) and may be implicated in a better BP control (Kahleová et al., 2002) .
The results, herein reported, were obtained by the use of 5-MTHF, the active form of folate (Nijhout et al., 2004) , in high dose. High doses of folates, 5 mg/day (van DiJk et al., 2001; Mangoni et al., 2002) , or 50 mg i.v./week (Anderson et al., 2006) , were also used in previous trials. Whether low dose of folate can achieve the same results is not clear. Nevertheless, the metabolic and BP effects of 5-MTHF in high doses, whether maintained in the long term, may contribute to primary cardiovascular prevention of aging women.
